The melanotan 1 vs 2 comparison is the fundamental decision in melanocortin peptide research — two compounds that both produce tanning through melanocortin receptor activation but differ dramatically in selectivity, side effect profile, and the range of additional effects they produce. Melanotan 1 (afamelanotide) is a selective MC1R agonist that produces tanning with minimal off-target effects — so selective that it received EU regulatory approval as Scenesse for erythropoietic protoporphyria. Melanotan 2 is a non-selective melanocortin agonist that activates MC1R (tanning), MC3R (energy homeostasis), MC4R (sexual arousal, appetite), and MC5R (sebaceous gland function) — producing a broader range of effects beyond tanning alone.

PSPeptides carries both compounds in two formats: nasal sprays (Melanotan I Nasal Spray and Melanotan II Nasal Spray) for needle-free convenience, and injectable vials (Melanotan I $39.99, Melanotan II $39.99) for maximum bioavailability. This guide covers the complete melanotan 1 vs 2 comparison: receptor pharmacology, tanning efficacy, side effects, regulatory status, dosing, and which compound fits which research question.

Melanotan 1 vs 2: The Complete Comparison Table

Melanotan 1 vs 2: The Receptor Selectivity Difference

The most important distinction in the melanotan 1 vs 2 comparison is receptor selectivity — and it determines everything else about each compound’s effects. MC1R is the receptor on melanocytes that controls melanin production. When MC1R is activated — by either melanotan 1 or 2 — melanocytes increase eumelanin synthesis, producing a tan. Both compounds do this effectively. The difference is what ELSE happens.

Melanotan 1 stops at MC1R. It activates the tanning receptor and essentially nothing else at standard research doses. This selectivity is why melanotan 1 has a regulatory approval (Scenesse, EU) — it does one thing with minimal off-target effects, making its safety profile characterizable and approvable.

The structural difference between the two compounds helps explain this receptor selectivity divergence. Melanotan 1 (afamelanotide) is a linear 13-amino acid analog of α-melanocyte-stimulating hormone (α-MSH) with a single modification — substitution of Met4 with a norleucine residue — that enhances receptor binding affinity and protease resistance while maintaining selectivity for MC1R. Melanotan 2 is a cyclic 7-amino acid compound (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) that adopts a conformation allowing simultaneous interaction with multiple melanocortin receptor subtypes. This structural difference — linear vs cyclic, selective vs non-selective — is the foundation of the entire melanotan 1 vs 2 pharmacological comparison.

Melanotan 2 activates four melanocortin receptors simultaneously. MC1R produces tanning. MC4R produces sexual arousal effects (the same receptor PT-141/bremelanotide targets — the PT-141 guide covers this pathway). MC3R influences energy homeostasis. MC5R affects sebaceous gland function. In the melanotan 1 vs 2 comparison, this multi-receptor activation is both melanotan 2’s advantage (more effects per compound) and its limitation (more potential side effects).

Melanotan 1 vs 2: The Tanning Comparison

For tanning-only research, the melanotan 1 vs 2 comparison favors melanotan 1. Both produce comparable tanning effects through MC1R activation, but melanotan 1’s selectivity means the tanning occurs without the nausea, libido changes, appetite effects, and pronounced mole darkening that melanotan 2’s multi-receptor activation can produce. Published research on afamelanotide (melanotan 1) documents consistent, dose-dependent eumelanin production with a safety profile clean enough for regulatory approval. For researchers whose only research question is melanin production, melanotan 1 provides the cleanest answer.

However, some researchers prefer melanotan 2 for tanning precisely because of the additional MC4R effects — the libido enhancement is considered a benefit rather than a side effect for some research applications. In the melanotan 1 vs 2 comparison, the “better” compound depends entirely on whether you want tanning-only (MT-1) or tanning-plus (MT-2).

From a mechanistic standpoint, both compounds in the melanotan 1 vs 2 comparison stimulate the same final pathway: α-MSH activation of MC1R triggers adenylyl cyclase, increases cyclic AMP, activates MITF (Microphthalmia-associated Transcription Factor), and upregulates tyrosinase — the rate-limiting enzyme in melanin synthesis. The result is eumelanin deposition in keratinocytes, producing visible skin darkening. The difference is that melanotan 1 accomplishes this through dedicated MC1R binding without interacting with other melanocortin receptors, while melanotan 2’s cyclic structure allows it to bind across the receptor family. Researchers focusing purely on this eumelanin synthesis pathway will find melanotan 1 the more mechanistically controlled research tool.

Tanning onset timing is similar between the two compounds in the melanotan 1 vs 2 comparison. Published afamelanotide data shows initial pigmentation increases within 7-14 days, with maximum tanning typically observed at 4-6 weeks. Anecdotal reports on melanotan 2 suggest similar timelines for tanning onset, though the broader receptor activation can produce earlier subjective effects (flushing, libido response) that may precede visible tanning. For comparative tanning research, researchers typically assess outcomes at weeks 2, 4, and 8 using reflectance spectrophotometry or clinical photography against standard Fitzpatrick reference cards.

Melanotan 1 vs 2: Safety and Side Effect Profiles

The melanotan 1 vs 2 comparison strongly favors melanotan 1 on safety documentation. As the active ingredient in Scenesse (EU-approved by the European Medicines Agency), melanotan 1/afamelanotide has undergone formal clinical trials, safety reviews, and post-marketing surveillance — producing the most comprehensive safety dataset of any melanocortin tanning peptide. Common effects are limited to mild injection site reactions and occasional nausea.

Melanotan 2 has a less characterized safety profile because it has not undergone regulatory review. Community-documented effects include: nausea (moderate during loading, usually transient), facial flushing, pronounced darkening of existing moles and freckles (requiring mole monitoring), libido enhancement, mild appetite suppression, and rare reports of dizziness. Most effects are transient and dose-dependent. In the melanotan 1 vs 2 comparison, researchers prioritizing the most conservative safety approach choose melanotan 1.

Melanotan 1 vs 2: Fitzpatrick Skin Type Considerations

Fitzpatrick skin type is an important variable when comparing melanotan 1 vs 2 for tanning research. The Fitzpatrick scale classifies skin into six phototypes based on melanin content and UV response: Type I (always burns, never tans) through Type VI (deeply pigmented, never burns). Research on afamelanotide (melanotan 1) initially focused on Fitzpatrick Types I and II subjects with erythropoietic protoporphyria — individuals whose photosensitivity made sun exposure clinically dangerous. In these populations, melanotan 1 produced protective eumelanin increases that enabled meaningful sun exposure without phototoxic reactions.

For melanotan 2, anecdotal and informal research data suggests similar responses across Fitzpatrick types, with the non-tanning effects (nausea, libido enhancement) appearing consistently across skin types but tanning magnitude varying based on baseline melanocyte activity. Researchers with darker baseline skin (Fitzpatrick Types IV-VI) may observe less dramatic visual tanning changes with either compound due to higher baseline melanin levels — though the cellular mechanisms of MC1R stimulation remain consistent regardless of skin type. Understanding Fitzpatrick classification helps researchers frame their melanotan 1 vs 2 data in the appropriate physiological context.

When designing a melanotan 1 vs 2 research protocol that accounts for skin type, researchers should note that individuals with higher baseline melanin have more pre-existing eumelanin in follicular units, which means the incremental change from peptide administration may be more subtle visually while still representing a measurable increase in melanin synthesis at the cellular level. Published afamelanotide research consistently stratifies results by Fitzpatrick type, and the 2015 NEJM trial on afamelanotide enrolled exclusively Type I-III subjects, making its findings most directly applicable to fair-skinned research contexts.

Melanotan 1 vs 2: The Nasal Spray Advantage at PSPeptides

PSPeptides uniquely offers both melanotan 1 vs 2 options in the nasal spray format — eliminating the injection barrier for both compounds. Melanotan I Nasal Spray for selective, tanning-focused research with zero needles. Melanotan II Nasal Spray for multi-receptor melanocortin research with zero needles. Both arrive ready to use — no reconstitution, no syringes, no preparation. For researchers who prefer injectable administration with maximum bioavailability, PSPeptides also carries both compounds as injectable vials at $39.99 each with the free reconstitution calculator for precise dose preparation.

Melanotan 1 vs 2: Which Should You Choose?

The melanotan 1 vs 2 decision framework: Choose Melanotan I Nasal Spray when your research focuses on tanning/melanin production only, when you want the safest characterized compound (EU regulatory data), when you are Fitzpatrick Type I-II (fair skin, more sensitive to melanocortin effects), or when you want to minimize side effects. Choose Melanotan II Nasal Spray when your research involves multiple melanocortin pathways (tanning + sexual function + appetite), when the libido enhancement is a desired research variable, or when you want the broader melanocortin receptor activation profile.

Both compounds in the melanotan 1 vs 2 comparison are available at PSPeptides. Free shipping, same-day processing including Sundays, Affirm/Afterpay at zero fees, discrete plain white mailer packaging. The side effects guide covers broader safety considerations. The stacking guide covers combination approaches. PubMed indexes melanotan research. Wikipedia covers afamelanotide/Melanotan I. Wikipedia covers Melanotan II.

Melanotan 1 vs 2: Published Research and Clinical Evidence

The melanotan 1 vs 2 comparison is underscored by a significant difference in published research depth. Melanotan 1 (afamelanotide) has the most robust clinical evidence of any melanocortin tanning peptide, supported by Phase II and Phase III clinical trials that led to EU regulatory approval as Scenesse. A landmark randomized controlled trial published in the New England Journal of Medicine (2015) enrolled 74 erythropoietic protoporphyria subjects and demonstrated that afamelanotide implant (16mg) significantly increased pain-free sun exposure time — with treated subjects gaining a median 69.4 hours of direct sun exposure versus 40.8 hours for placebo over a six-month period, a statistically significant improvement (p=0.04). The safety profile showed only mild injection site reactions as meaningful adverse events.

For melanotan 2, published research is more limited due to its non-approved status. A frequently cited early study by Dorr et al. (1996) demonstrated dose-dependent tanning in human subjects at doses of 0.01 to 0.16 mg/kg, with nausea being the most commonly reported adverse effect at higher doses. Research comparing MC4R agonism — the mechanism melanotan 2 activates for libido effects — has been more extensively studied through bremelanotide (PT-141), which is a related compound. This broader melanocortin receptor literature informs researchers studying melanotan 2’s non-tanning pathways. In the melanotan 1 vs 2 literature review, afamelanotide has substantially more peer-reviewed clinical data.

A 2010 Phase II trial from the University of Arizona documented afamelanotide’s tolerability across 45 subjects, with 93% of participants experiencing measurable increases in skin pigmentation within two weeks of administration. Adverse events were predominantly injection site reactions (grade 1-2) with no serious adverse events reported. This body of research — combined with post-marketing safety surveillance from Scenesse’s commercial use — gives researchers a substantially more complete picture when evaluating melanotan 1 vs 2 from a documented evidence standpoint. Researchers studying melanotan 2 should also consult the published melanocortin receptor pharmacology literature to understand the broader multi-receptor effects.

Melanotan 1 vs 2: Research Protocol Considerations

Understanding storage, handling, and administration format is essential when planning any melanotan 1 vs 2 research project. Both compounds are sensitive to heat and UV light and require proper storage to maintain peptide integrity. For injectable vials, both compounds should be stored lyophilized at -20°C for long-term storage or at 4°C refrigerated for short-term use (up to 4 weeks after reconstitution). PSPeptides provides batch-specific COAs confirming peptide purity at 99%+ by HPLC before shipment. Researchers can verify purity standards using the peptide COA guide to understand what these certificates demonstrate.

For injectable administration, reconstitution typically uses bacteriostatic water. The reconstitution guide outlines the step-by-step process for preparing peptide vials safely. PSPeptides also offers a free peptide dosage calculator for researchers computing precise concentrations. For those new to peptide research or preferring needle-free administration, both compounds are available as ready-to-use nasal sprays — eliminating reconstitution entirely. The nasal spray format is particularly valuable for the melanotan 1 vs 2 comparison because it allows researchers to study both compounds under identical administration conditions.

Storage stability data for melanocortin peptides shows that lyophilized powder is stable for 24+ months when stored correctly at -20°C. Once reconstituted, the melanotan 1 vs 2 comparison shows similar stability windows: both maintain activity for approximately 30 days when refrigerated at 2-8°C. Researchers working with the peptide storage guide for melanocortin compounds should avoid repeated freeze-thaw cycles, as these can degrade peptide structure and reduce biological activity. Single-use aliquoting after reconstitution preserves peptide integrity across the research period.

Melanotan 1 vs 2: Can They Be Studied Together?

A frequently asked question in the melanotan 1 vs 2 research space is whether both compounds can be studied in a combined protocol. From a pharmacological standpoint, this is theoretically plausible — melanotan 1 provides MC1R-selective tanning stimulus, while melanotan 2 adds the multi-receptor component. However, combined-use research introduces complexity: overlapping MC1R activation could produce additive or saturating effects at the receptor level, and it becomes difficult to attribute specific outcomes to one compound versus the other.

Most research designs choose one compound based on the primary research question: if the study centers on tanning and pigmentation only, melanotan 1 provides a cleaner experimental model. If the research includes libido, appetite suppression, or multi-pathway melanocortin effects, melanotan 2 addresses those variables directly. For researchers considering peptide stacking broadly, the peptide stacking guide covers general principles for combining compounds in research contexts. The melanotan 1 vs 2 decision ultimately comes down to which receptor pathways are relevant to the specific research question being investigated.

PSPeptides: Quality, Supplies, and 24/7 Support

PSPeptides provides 99%+ HPLC-verified peptides with batch-specific COAs from independent laboratories. US manufacturing. Same-day processing seven days a week including Sundays. Free shipping on every domestic order. Free international shipping to 30+ countries over $150. Zero fees on Affirm, Afterpay, Zelle, cards, Apple Pay, Google Pay. Discrete plain white mailer packaging. 24/7 support via live chat, email ([email protected]), phone/text (551) 284-2670. 5-star rating from thousands of verified customers at pspeptides.com/shop.

Understanding melanotan 1 vs 2 is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is the difference between melanotan 1 and 2?

Melanotan 1 is MC1R-selective (tanning only, minimal side effects, EU-approved). Melanotan 2 activates MC1R + MC3R + MC4R + MC5R (tanning + libido + appetite effects). Both available at PSPeptides.

Which is safer, melanotan 1 or 2?

Melanotan 1 has the stronger safety profile — it received EU regulatory approval (Scenesse) based on clinical trial data. Melanotan 2 has more documented side effects due to non-selective receptor activation.

Does PSPeptides sell melanotan nasal sprays?

Yes. Both Melanotan I and Melanotan II as ready-to-use nasal sprays — zero injection, zero reconstitution. Also available as injectable vials ($39.99 each).

Which melanotan is better for tanning?

Both produce comparable tanning. Melanotan 1 provides tanning with fewer side effects (selective). Melanotan 2 provides tanning plus libido and appetite effects (non-selective). Choose based on your research goals.

All PSPeptides products are sold exclusively for research and laboratory use.